Abstract Search

ea0046p17 | (1) | UKINETS2016

UK Phase IV, Observational study to assess Quality of Life in patients (pts) with pancreatic neuroendocrine tumours (pNETs) receiving treatment with Everolimus: The “Real-World” OBLIQUE Study

Ramage John , Punia Pankaj , Olusola Faluyi , Frilling Andrea , Meyer Tim , Kapur Gaurav , Cave Judith , Wadsley Johnathan , Cummins Sebastian , Farrugia David , Starling Naureen , Wall Lucy , Saharan Ruby , Valle Juan

Background: Everolimus, a mammalian target of rapamycin inhibitor, is licensed for use in adult pts with advanced well-differentiated pNETs in the UK. Limited Health-Related Quality-of-Life (HrQOL) data are available for everolimus therapy in these pts.Methods: This prospective study assessed changes in HrQoL (by monthly patient-reported EORTC QLQ-C30, -G.I.NET21 and EQ-5D questionnaires), in pts with pNETs during the first 6 months (mo) of treatment wit...

0 shares

Endocrine Abstracts

UK Phase IV, Observational study to assess Quality of Life in patients (pts) with pancreatic neuroendocrine tumours (pNETs) receiving treatment with Everolimus: The “Real-World” OBLIQUE Study

BiosciAbstracts